Startup · $3.2m raised
Working on antibody therapies to target and eliminate disease-causing immune cells in autoimmune conditions
Programs: Breakthrough Victoria (University Innovation Platform)
Every investor coverage indicates participated in a round Fyton Bio raised.
| Investor | Rounds | Invested |
|---|---|---|
| Breakthrough Victoria | Pre-seed · Pre-seed · Accelerator | - |
| Monash University | Pre-seed · Pre-seed | - |
| Monash Ventures | Pre-seed | - |
| Monash Ventures Pre-Seed Fund | Pre-seed | - |
Companies Fyton Bio acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Fyton Bio. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
FytonBio secured one million dollars in pre-seed funding from Breakthrough Victoria and Monash University to develop antibody therapies for autoimmune diseases using Monash's GREAT platform.
Two Victorian backers put a combined $2.25 million into three university spinouts pursuing biologics, antibody drugs and delivery devices, launching a new $15 million pre-seed vehicle.
Also @AuManufacturing
Weekly roundup: Breakthrough Victoria and Monash University co-invest $2.25 million across three university healthtech spinouts, while Blackbird backs Hall, which helps businesses win visibility on AI platforms, with $2 million pre-seed.
Also Startup Daily
Breakthrough Victoria and Monash University put joint pre-seed backing into three life-sciences spinouts and launched the $15m Monash Ventures pre-seed fund, part of a $100m platform commercialising Victorian university research.
The investor's site reports a joint pre-seed investment with Monash University totalling $2.25 million across three health startups, and the launch of Monash Ventures' $15 million pre-seed fund for research commercialisation.
Also Breakthrough Victoria·SmartCompany·@AuManufacturing·@AuManufacturing